Morpheaform and Infiltrative BCC

01Clinical recognition is the first hurdle. Morpheaform BCC presents as an ill-defined, slightly indurated, ivory-white to pink plaque that resembles a scar, with no history of trauma to explain the appearance. It develops on chronically sun-damaged skin, classically the central face (nose, periorbital, perinasal, cheek). The lesion is often larger than it appears clinically, with finger-like extensions of tumor invading deep into the dermis.

02Dermoscopy of morpheaform BCC is the most subtle of all BCC subtypes. The most characteristic finding is structureless porcelain-white hypopigmentation, present in 75 percent of cases (Kim 2015), reflecting the dense dermal fibrosis of the morpheaform stroma. Arborizing telangiectasias are present in 51 percent but tend to be finer, with a smaller caliber and less branching than in nodular BCC. Ulceration is common (58 percent). Pigmented features are essentially absent (0 to 13 percent of morpheaform BCC) because the tumor is poorly differentiated and rarely produces melanin.

03Infiltrative BCC shows similar dermoscopic features but with more vascular components. Reiter's pooled analysis of 288 infiltrative BCCs reports arborizing vessels in 76 percent, ulceration in 44 percent, and short fine telangiectasias in 40 percent. Shiny white-red structureless areas appear in 39 percent and reflect intermediate fibrosis. Pigmented features remain rare, with leaf-like areas present in only 4 percent.

04Reflectance confocal microscopy is decisive for both morpheaform and infiltrative subtypes. The pathognomonic feature is the dark silhouette: a hyporefractile, footprint-like shadow of basaloid tumor proliferation embedded in a context of bright compact collagen. In Longo's 2014 series, dark silhouettes appeared in 77 percent of infiltrative BCCs and gave a 12.8-fold higher odds of infiltrative diagnosis. Bright compact collagen surrounding tumor islands was present in 95 percent. Notably, infiltrative BCC was the most common diagnosis when small tumor islands, big tumor islands, and cords connected to the epidermis were all absent.

05Dermoscopic margin mapping pre-Mohs is increasingly used to plan the first surgical stage. Pan 2012 demonstrated feasibility of preoperative RCM mapping of BCC margins. The handheld RCM probe (Longo 2024) makes this practical in real-world clinics. Margins identified by RCM correlate well with Mohs frozen-section margins, though depth limitations of standard wide-probe RCM (250 micrometers) require OCT or LC-OCT for deeper assessment.

06Recurrence patterns reflect the infiltrative growth. The 5-year recurrence rate for morpheaform and infiltrative BCC is 5 to 17 percent depending on size, anatomic location, and surgical technique. Mohs reduces recurrence substantially: a 10-year follow-up of the Mosterd RCT showed 4.4 percent recurrence with Mohs vs 12.2 percent with SSEPME for high-risk BCCs. Recurrence often appears as a subtle pearly papule at the edge of the original scar, sometimes years after initial treatment, and dermoscopy is essential for early detection.

07Management algorithm is straightforward but high-stakes. Morpheaform and infiltrative BCC are NCCN high-risk by histology alone, regardless of size or location. First-line is Mohs micrographic surgery for tissue conservation and margin control. Adjuvant radiation may be considered for resections with positive margins, large tumors, or perineural invasion. Locally advanced or metastatic disease unresponsive to surgery and radiation is treated with hedgehog pathway inhibitors (vismodegib, sonidegib) or, for selected patients, immune checkpoint inhibitors.